Evolus to Participate in The Jefferies Global Healthcare Conference
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference
Evolus to Report First Quarter Financial Results on May 4, 2026
JPMorgan Chase & Co. Decreases Stake in Evolus, Inc. $EOLS
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Evolus (NASDAQ:EOLS) Insider Sells $14,815.25 in Stock
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
Evolus, Inc. (NASDAQ:EOLS) Receives $17.50 Average Target Price from Analysts
Why Evolus Stock Soared Today
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ:EOLS) Receives $17.50 Consensus PT from Brokerages
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings
Frontier Capital Management Co. LLC Buys 457,533 Shares of Evolus, Inc. $EOLS
Brokerages Set Evolus, Inc. (NASDAQ:EOLS) Target Price at $21.25
Campbell & CO Investment Adviser LLC Makes New $434,000 Investment in Evolus, Inc. $EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
Evolus Reports Third Quarter 2025 Financial Results
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus to Participate in 2025 Stifel Healthcare Conference
Evolus to Report Third Quarter Financial Results on November 5, 2025
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates
Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline
Evolus to Report Second Quarter Financial Results on August 5, 2025
Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)